Sign in

    Bill Keay

    Research Analyst at RBC Capital Markets

    Bill Keay is an analyst at RBC Capital Markets, specializing in equity research with a focus on life sciences and biotechnology companies. He is known for covering firms such as Arrowhead Pharmaceuticals and other leading biopharmaceutical companies, consistently delivering insightful investment analysis and forecasts. Keay has built a solid career in capital markets, joining RBC after previous experience in the sector and earning recognition for his sector knowledge. Holding relevant securities licenses and maintaining a strong professional track record, Bill Keay is regarded for his analytical rigor and industry expertise.

    Bill Keay's questions to Intercontinental Exchange (ICE) leadership

    Bill Keay's questions to Intercontinental Exchange (ICE) leadership • Q2 2025

    Question

    Bill Keay, on behalf of Ashish Sabadra from RBC Capital Markets, asked about the key drivers behind the margin expansion observed in the Mortgage Technology segment.

    Answer

    CFO Warren Gardiner attributed the margin improvement to two main factors: the realization of cost synergies from the Black Knight integration and a planned reallocation of certain operations and technology expenses to the corporate level as part of the integration. He encouraged looking at the overall company margin, which also expanded.

    Ask Fintool Equity Research AI

    Bill Keay's questions to Intercontinental Exchange (ICE) leadership • Q2 2025

    Question

    Bill Keay, on behalf of Ashish Sabadra at RBC Capital Markets, asked about the key drivers behind the margin expansion observed in the Mortgage Technology segment during the quarter.

    Answer

    CFO Warren Gardiner explained the margin expansion was driven by two main factors: a planned reallocation of certain operational and technology expenses to the corporate level as part of the integration, and the increasing realization of cost synergies from the Black Knight acquisition. He encouraged analysts to also focus on the two-point margin expansion for the overall company.

    Ask Fintool Equity Research AI